Contract manufacturers prepare for anticipated biosimilars manufacturing demands through expansion and acquisition.
Compared to traditional small-molecule generics, the R&D costs and development times for biosimilars are significantly greater. With demand for services in the biosimilars space set to soar, many contract development and manufacturing organizations are increasing their capabilities in this field. Expansions including in-house development, partnerships and joint ventures, or bolt-on acquisitions are summarized.
over 9 years ago
Customer Relationship Management in Contract Manufacturingover 9 years ago
Getting Biopharmaceutical Tech Transfer Right the First Timeover 9 years ago
CMOs Tackle New Challengesover 9 years ago
Insourcing vs Outsourcing: Choosing the Right Strategyover 9 years ago
Operations and Quality Oversight of CMOsover 9 years ago
Quality Metrics and CMO Agreement
